Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mut...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Nat Commun
Huvudupphovsmän: Van Emburgh, Beth O., Arena, Sabrina, Siravegna, Giulia, Lazzari, Luca, Crisafulli, Giovanni, Corti, Giorgio, Mussolin, Benedetta, Baldi, Federica, Buscarino, Michela, Bartolini, Alice, Valtorta, Emanuele, Vidal, Joana, Bellosillo, Beatriz, Germano, Giovanni, Pietrantonio, Filippo, Ponzetti, Agostino, Albanell, Joan, Siena, Salvatore, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Montagut, Clara, Bardelli, Alberto
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5155160/
https://ncbi.nlm.nih.gov/pubmed/27929064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms13665
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk